{"prompt": "['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 10 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'CCI', '8.', 'The subject has any uncontrolled or serious disease or any medical or', 'surgical condition that may either interfere with the interpretation of the trial', 'results and/or put the subject at significant risk (according to the', \"Investigator's judgment) if the subject takes part to the trial.\", '9.', 'The subject has known or suspected allergies or sensitivities to any', \"components of any of the study drugs (see Investigator's Brochure).\", 'Investigational product:', 'Location of treated area:', 'Face: Chin, left cheek, right cheek, nose, and forehead', 'Truncal region : right and left upper back, right and left shoulders and right and left', 'upper anterior chest', 'Efficacy Assessments :', 'Efficacy endpoints', '.', 'Success Rate, defined as the percentage of subjects who achieve an IGA score', 'of 1 (Almost Clear) or 0 (Clear) AND at least a 2-grade improvement from', 'Baseline to Week 12 and Week 24', 'CCI', '.', 'Success Rate, defined as the percentage of subjects who achieve a PGA score of', '1 (Almost Clear) or 0 (Clear) AND at least a 2-grade improvement from Baseline', 'to Week 12 and Week 24', 'CCI', '. Percent change in facial non-inflammatory lesion counts from Baseline to week', '12 and week 24.']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 11 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'Percent change in facial inflammatory lesion counts from Baseline to week 12 and', 'week 24.', 'Percent change in truncal non-inflammatory lesion counts from Baseline to week', '12 and week 24.', 'Percent change in truncal inflammatory lesion counts from Baseline to week 12', 'and Week 24.', \"Subject's assessment of facial acne improvement\", 'Safety assessment:', 'Safety assessments will be conducted for all subjects at Screening/baseline and all', 'subsequent visits until the Week 24 Visit. The safety parameters are Adverse Events,', 'local tolerability assessments.', 'Measurement criteria', 'Subject-reported outcomes', 'Quality Of Life questionnaires:', 'Dermatology Life Index questionniare (DLQI) questionnaires comparing', 'Baseline to Weeks 12 and 24 or Early termination', 'CompAQ (for >16 years age) comparing Baseline to Weeks 12 and 24', 'or', 'Early termination', 'EQ-5D-5L comparing Baseline to Weeks 12 and 24 or Early termination', 'Subject satisfaction questionnaire at Week 12/24/Early termination', 'Efficacy', \"Investigator's Global Assessment (IGA): acne severity of the face on a scale\", 'from 0 (Clear) to 4 (Severe) at each visit. Total lesion, non-inflammatory', 'lesion (open and closed comedones), inflammatory lesion (papules,', 'pustules) on the face (including the nose) at each visit', 'Physician Global Assessment (PGA): acne severity of the trunk on a scale', 'from 0 (Clear) to 4 (Severe) at each visit. Total lesion, non-inflammatory', 'lesion (open and closed comedones), inflammatory lesion (papules,', 'pustules) on trunk at each visit', 'Safety', 'Local tolerability parameters (erythema, scaling, dryness', 'and', 'stinging/burning) will be evaluated at each visit on a 4-point scale ranging', 'from 0 (none) to 3 (severe).', 'CCI', 'Adverse Events which includes AEs, SAE, AESI and Death', 'Other', 'CCI']['GALDERMA R&D', 'RD.06.SPR.118295 Protocol V02 04Jun2019', 'Page 12 of 88', 'SYNOPSIS', 'Clinical Trial Title: A Multi-Center Study to Evaluate Subject Reported Outcomes with use of Trifarotene 50 g/g', 'Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris', 'Analysed variables', 'Subject-reported outcomes', 'DLQI/cDLQI and CompAQ at Baseline and Week 12, 24/Early termination', 'Subject satisfaction questionnaires at Week 12, 24/Early termination', 'EQ-5D-5L at baseline and Week 12, 24/Early termination', 'Efficacy variable', 'Percent change in the facial IL NI', 'CC', 'lesion count from', 'Baseline to Weeks 12 and 24', 'CCI', 'Percent change in the trunk IL, NI', 'CC', 'lesion count from', 'Baseline to Weeks 12 and 24', 'Success rate of IGA as the percentage of subjects who achieved an IGA', 'with a score of 1 (almost clear) or 0 (Clear) AND an at least a 2-grade', 'improvement from Baseline at each study visit.', 'Success rate of PGA as the percentage of subjects who achieved a PGA', 'with a score of 1 (almost clear) or 0 (Clear) AND an at least a 2-grade', 'improvement from Baseline at each study visit.', 'CCI', 'Safety variables', 'Local tolerability parameters will be assessed at Baseline and each post', 'baseline visits, on all treated areas.', 'Local tolerance: Raw value at each visit and worst-score across vist, % of', 'Subjects across scores at each post-baseline visit', 'Incidence of adverse events (AESI, SAEs, Death, leading to discontinuation', 'or early termination)', 'Other', 'Principal statistical method:', 'The Intent-to-Treat (ITT) population consists of all enrolled subjects. The Safety', 'population (SAF) consists of the ITT population, who applied at least one dose of', 'treatment.', 'The main objective of this study is to evaluate the subject reported outcomes with', 'trifarotene with 12 and up to 24 weeks of treatment.', 'All variables will be descriptively summarized. All safety endpoints will be sumarized', 'based on SAF population and Quality of life and Efficacy endpoints will be sumarized']\n\n###\n\n", "completion": "END"}